absci®

```
from absci import de_novo_model
model = de_novo_model.load_latest()
antigen = model.load_pdb("7olz.pdb",
chain="A")
antibodies = model.predict(antigen, N=300000)
```

```
from absci_library import codon_optimizer
library
= codon_optimizer.reverse_translate(library)
library.to_csv("covid-antibody-designs.csv")
library.to_wet_lab(assay="ACE")
```

```
from absci import lead_opt_model
lead_optimizer = lead_opt_model.load_latest()
library.naturalness =
lead_optimizer.naturalness(library)
lead_optimizer.optimize(library).to_wet_lab(as
say="SPR")
```

DRUG CREATION

AN INTRODUCTION TO ABSCI &
AI DRUG DISCOVERY

```
from absci import genetic_algorithm; parameters=["maximize|binding_affinity:pH=7.5", "minimize|binding_affinity:pH=6.0",
"maximize|human_naturalness"]; library = genetic_algorithm.multiparametric_optimization(library, parameters, evolutions=100);
library.to_wet_lab(assays=["ACE", "SPR", "Bioassays"])
```

```
absci_library import codon_optimizer
ary =
n_optimizer.reverse_translate(library)
ary.to_csv("covid-antibody-designs.csv")
ary.to_wet_lab(assay="SPR")
```

An introduction to Absci & AI Drug Discovery

```
from absci import lead_opt_model
lead_optimizer = lead_opt_model.load_latest
library.naturalness =
lead_optimizer.naturalness(library)
lead_optimizer.optimize(library).to_wet_lab
say="SPR")
```



Disclaimers

Forward-Looking Statements

Certain statements in this presentation that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects,” “predicts,” “advancing,” “aim,” “potential,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding our strategy, estimated speed, cost advantages, improved success rates, and expanded intellectual property opportunities from developing therapeutics leveraging our AI drug creation platform, the effective incorporation of our technology in drug design and discovery to accelerate drug development and increase probability of success, advancements toward in silico drug design and creation, research and technology development collaboration efforts, potential milestone and royalty payments due under our collaboration agreements, projected costs, prospects, plans and objectives of management, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to the development of our technology, our ability to secure milestone payments and royalties, our ability to effectively conduct research, drug discovery and development activities with respect to our internal programs and to collaborate with our partners or potential partners with respect to their research, drug discovery and development activities; along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Market and Statistical Information

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the data generated by independent parties and cannot guarantee their accuracy or completeness.

Trademark usage

This presentation/document/webpage contains references to our trademarks and service marks and to those belonging to third parties. Absci®, theAbsci logo mark (a), SoluPro®, Bionic SoluPro®, and SoluPure® are Absci registered trademarks with the U.S. Patent and Trademark Office. We also use various other trademarks, service marks and trade names in our business, including the the Absci AI logo mark (ai), the Unlimit with us mark (Unlimit with us), the unlimit symbol (unlimit), Bionic protein ™, Bionic Enzyme ™, Bionic Antibody™, Denovium ™, Denovium Engine ™, Drug Creation ™, Integrated Drug Creation™, HiPrBind™, HiPrBind Assay™, Translating Ideas into Drugs™, Translating Ideas into Impact™, We Translate Ideas into Drugs™, Creating drugs at the speed of Ai™, Better biologics for patients, faster™, Breakthrough therapeutics at the click of a button, for everyone™, and We Translate Ideas into Impact™. All other trademarks, service marks or trade names referred to in this presentation/document/webpage are the property of their respective owners. Solely for convenience, the trademarks and trade names in this presentation/document/webpage may be referred to with or without the trademark symbols, but references which omit the symbols should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

Absci is a generative AI drug creation company.

OUR MISSION IS SIMPLE: CREATE BETTER BIOLOGICS FOR PATIENTS, FASTER.

The drug discovery paradigm is ripe for disruption

- Historically, biologic drug discovery is risky, time-consuming, and expensive - with a >90% failure rate.
  - It takes an average of 10 years and more than $1 billion to bring just one new drug to market, limiting the scope and number of treatments that drugmakers can pursue.
- Conventional methods of drug discovery involve a long, iterative process resulting in candidates with suboptimal attributes, as steps taken to optimize one attribute may worsen another.
  - These methods are also unable to generate antibodies toward “undruggable” targets (e.g. GPCRs, ion channels), thereby limiting the diseases they are able to treat.
- With the current paradigm, it takes 5.5 years to go from discovery to IND, with a <5% success rate from discovery to launch.



Conventional Methods (e.g. Immunization, Phage Display)

AN EMERGING, INNOVATIVE APPROACH

Absci is uniquely positioned in the emerging field of AI drug discovery

- The opportunity to apply AI in drug discovery is an emerging field, and an increasingly significant topic of interest to pharma and large tech companies.

- Within the landscape of AI drug discovery, many companies are focused on small molecules, while Absci's focus is on large molecule drugs, or biologics.
  - Generative AI relies on vast amounts of data to be functional, and there is a wealth of existing data available for *small molecules*.
  - By contrast, data for *biologics* is less readily accessible – this is the problem Absci is uniquely positioned to solve.

- The field of biologics is also where we believe we can add the most value within the broader healthcare landscape.
  - Today, approximately 1/3 of all pre-clinical activity in progress is focused on next-generation biologics.
  - The Inflation Reduction Act could also potentially support a more accelerated industry shift from small molecules to biologics, further bolstering growth in this field.
- With our proprietary platform and groundbreaking technology, Absci is positioned as a leader in the field of AI drug discovery for biologics.

ai™

A BETTER, FASTER PATH TO NEW MEDICINES

Designing antibodies "from scratch"

- Most drug discovery approaches today look to existing antibody libraries for incremental improvements.
  - We recently showed how we design *de novo* antibodies "from scratch" on a computer.
- Our zero-shot AI approach designs antibodies without prior learning on the specific target, generating candidates unlike those found in existing databases.
- Our wet lab can experimentally validate the candidates that work right out of the computer - without the slow and costly step of lead optimization.
- This potentially reduces the time it takes to get new drug leads into the clinic, while unlocking treatments for traditionally "undruggable" diseases and improved therapeutic possibilities for many others.
  - Biologics, and the ability to pursue "undruggable" targets, offer the greatest promise for indications never previously able to see benefits from traditional small molecule drugs.

```
from absci import de_novo_model model = de_novo_model.load_latest() antigen = model.load_pdb("7olz.pdb",
chain="A") antibodies = model.predict(antigen, N=300000) from absci_library import codon_optimizer library
= codon_optimizer.reverse_translate(library) library.to_csv("covid-antibody-
designs.csv") library.to_wet_lab(assay="ACE")
```

Absci is changing the paradigm from drug discovery to drug creation

VALUE FOR PARTNERS AND PATIENTS

Absci's capabilities give drugmakers new potential

- Absci enables a shift from drug *discovery* to drug *creation*.
  - Instead of looking for the needle in a haystack, we are creating the needle.

- We unlock new possibilities in *de novo* design, lead optimization, target identification, and antibody-drug conjugate (ADC) development, where drugmakers seek candidates with tailored target binding, better manufacturability, lower immunogenicity, and shorter development times.
  - Absci adds value to pharma partners by enabling capabilities they could otherwise not achieve themselves, and potentially increase ultimate success in the clinic.

- By enabling biologic drug discovery to happen more quickly and efficiently, we help our partners bring better drugs to more patients everywhere.

THE POWER OF GENERATIVE AI

By *creating* the antibodies with generative AI, we can *design* candidates with desired attributes

Instead of the long, iterative process of sequentially optimizing parameters one by one, our platform is engineered to design an antibody with all of the desired attributes from the start.

- This workflow would potentially reduce the time to clinic, lower the cost of discovery work, and lead to a higher ultimate probability of success.

This multiparametric optimization allows us to design for:

- Target - antibodies bind to specific foreign substances in the body, such as proteins on surface of bacteria, viruses, or cancer cells to help protect against infection and fight disease
- Affinity - the strength of the bond between an antibody and its target
- Epitope - the region on an antigen (e.g., virus, bacteria, cancer cell) recognized and bound by an antibody
- Developability - the ease with which an antibody can be developed into a drug for use in humans or other animals
- Manufacturability - the ease with which an antibody can be produced in large quantities
- Immunogenicity (inverse) - the ability of an antibody to trigger an immune response in the body

The Solution

At Absci, the future is now with our Integrated Drug Creation™ platform

DATA TO TRAIN

Proprietary wet-lab assays generate massive quantities of high-quality data for generative AI model training



AI TO CREATE

Advanced generative AI models used to “create” antibodies and next-gen biologics

WET LAB TO VALIDATE

Scalable wet-lab infrastructure capable of validating millions of unique AI-generated designs a week

WHY HASN'T GENERATIVE AI TRANSFORMED BIOLOGIC DRUG DISCOVERY?

Unlocking the potential of generative AI in biology requires scalable biological data

While small molecule libraries are widely available, biologics data is less readily accessible – Absci's platform solves for this constraint

Small Molecule v. Biologic



Extensive Libraries



Limited Data

Biologics require living organisms to produce drug variants for testing



Consistency and accurate data is limited

Unlocking the potential of generative AI in biology...



...requires generating scalable biological data

Absci's scalable biological data enables true generative AI for biologics drug discovery

Absci's ACE Assay™ generates data at >4,000x the throughput of traditional HT assays



Massive Training Data Sets



ABSCI'S END-TO-END PLATFORM SOLUTION

The leading full-stack AI platform for biologics drug creation

Leverage deep disease insights with novel approaches

Reverse Immunology for target discovery

AI-guided antibody drug creation

Biologics at a click of a button

AI guided antibody optimization

Multi-parameteric optimized antibodies



THE FLYWHEEL EFFECT WITH SCALABLE BIOLOGICAL DATA AND AI

Cycles completed within weeks

DATA TO TRAIN

Typical 6-week per cycle



WET LAB TO VALIDATE

AI TO CREATE

Absci's platform and rapid 6-week cycle times allow for:

01

Rapid iteration and improvement of AI models

02

Reduction of preclinical development timelines and increased probability of success

03

Accelerated achievement of mission and recruitment of top AI talent

04

Advanced insight and learnings of potential and progress of generative AI in biology

Absci is the first to design and validate novel antibodies* using zero-shot generative AI

***March 2023**

Designed and validated novel antibodies by CDRs design using zero-shot generative AI - unlocking the potential to go from target to therapeutic antibody at a click of a button
(Shanehsazzadeh et al. 2023)

Feb 2023

Solved longstanding codon optimization problem and created largest expression database of its kind to optimize DNA codon sequences and maximize protein yield. Important for biomanufacturing.
(Constant et al. 2023)

Aug 2022

Used artificial intelligence to simultaneously optimize multiple parameters important to drug discovery and development
(Bachas et al. 2022)

DE NOVO DRUG CREATION *IN SILICO*

De novo drug creation with ‘zero-shot’ generative AI



- Absci’s breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic
- Zero-Shot: Model has never seen an antibody that binds to the target or homologs
- Binders were identified straight out of the model – no lead optimization was performed
- Demonstrated across four therapeutic targets: HER2, VEGF-A, COVID omicron, undisclosed target

Potential to enable our partners with

ACCESS TO NOVEL DISEASE BIOLOGY

Ability to address elusive drug targets, e.g. GPCRs, ion channels



Enabling “first-in-class”

SUPERIOR DRUG ATTRIBUTES

Multi-valent biologics, increased half-life, conditional pH dependent binding



Enabling “best-in-class”

INCREASED SUCCESS RATE

Multi-parametric optimization creates higher quality biologics



Higher program NPVs

EXPANDED INTELLECTUAL PROPERTY SPACE

AI-drug creation generates broader IP for “first-in-class” and finds new IP for fast follower / “best-in-class”



Defense + “best-in-class”

Accelerating time to clinic while increasing probability of success

Better biologics for patients, faster



Creating Compounding Value for Shareholders and Partners

Illustrative Economic Structure of a Successful Drug Discovery Partnership



*Illustrative example; assuming successful commercialization. Regulatory milestone captured in clinical development, and single digit royalty rates

INTERNAL ASSET DEVELOPMENT UNDERWAY

Internal pipeline of assets to complement discovery partnerships

- In addition to ongoing and future discovery partnerships, Absci is developing our own pipeline of internal assets.
- With our capabilities and team, Absci is well positioned to advance our own pipeline through early-stage clinical programs and demonstrate the power of our platform.
- **Plan to opportunistically partner internal programs at Candidate through early Clinical stages**
  - Create and capture significant near- and long-term value
  - Additional platform validation for investors and for business development
- Absci has built a world class team of leaders in drug discovery, including Dr. Andreas Busch, PhD as Chief Innovation Officer.
  - Over his career Dr. Busch has led discovery efforts for some of the globe's top pharma companies including Sanofi, Bayer, and Shire.
  - His leadership has resulted in 10 commercial drugs starting from bench to FDA approval with several more in late stage clinical development.

Internal program partnerships have attractive risk-return profiles

- Internal programs require additional upfront capital investment

but offer

- Larger partnership deal economics
- More optionality (develop to Candidate, IND, or early clinical)
- Greater NPV



Illustrative economic structure of a successful Discovery and Internal Program partnership

The AI Drug Creation Revolution is only just beginning

>160	Unlimiters with deep experience in AI, drug discovery, immunology, and synthetic biology
Leading AI team with expertise from:	NVIDIA, Google, MIT, Microsoft Research, Harvard University, insitro, X, Stanford University, OpenAI, Meta, Tesla
Biologics drug discovery expertise from:	Bayer, Takeda, Pfizer, Johns Hopkins Medicine, novo nordisk, Broad Institute, Shire, University of Oxford
77,000+ Square Feet	State-of-the-art drug creation and wet lab space in Vancouver WA, Absci AI Research (AAIR) lab in NYC, and the Innovation Centre in Zug Switzerland
~$450M	Capital raised to date

PARTNERSHIPS

Technology validated through industry-leading collaborations

"Merck leans into AI with $610M in biobucks for Absci drug discovery pact"

*"Absci's platform offers a compelling opportunity to design new biologic candidates and explore the expression of complex proteins."**

Dr. Fiona Marshall
Merck, Former SVP, Head of Discovery, Preclinical and Translational Medicine

"AstraZeneca types up $247M, AI-enabled oncology antibody design pact, joining Absci's list of pharma allies"

"This collaboration is an exciting opportunity to utilize Absci's de novo AI antibody creation platform to design a potential new antibody therapy in oncology."

Dr. Puja Sapra
AstraZeneca, SVP, Biologics Engineering & Oncology Targeted Delivery

"Absci collaborates with NVIDIA to accelerate vision of creating drugs *in silico*"

"Absci's powerful data generation and AI protein engineering platform is already helping the drug discovery industry, and NVIDIA is excited to help power and scale Absci's in silico technologies to achieve the best positive impact."

Kimberly Powell
Vice President of Healthcare

"Absci inks deal worth $650M with drug maker Almirall"

"Almirall chose Absci because their de novo platform brings truly novel innovation in solving the industry's most challenging targets facing high unmet medical need."

Dr. Karl Ziegelbauer
Almirall, EVP of R&D and CSO

1 https://investors.absci.com/news-releases/news-release-details/absci-announces-research-collaboration-merck
2 https://www.fiercebiotech.com/biotech/astrazeneca-inks-247m-ai-enabled-oncology-antibody-design-pact-joining-abscis-list-pharma
3 https://investors.absci.com/news-releases/news-release-details/absci-develops-groundbreaking-machine-learning-models-silico
4 https://www.bizjournals.com/portland/news/2023/11/14/absci-almirall-vancouver-biotech.html

Team of innovators and trailblazers to achieve the impossible

EXECUTIVE LEADERSHIP TEAM

SEAN MCCLAIN
Founder & CEO Director

ANDREAS BUSCH, PHD
Chief Innovation Officer

ZACH JONASSON, PHD
Chief Financial Officer and Chief Business Officer

JACK GOLD
Chief Marketing Officer

KARIN WIERINCK
Chief People Officer

AMARO TAYLOR-WEINER, PHD
SVP, Chief AI Officer

PENELOPE
Chief Morale Officer

BOARD OF DIRECTORS

KAREN MCGINNIS, CPA
Former CAO,
Illumina

FRANS VAN HOUTEN
Former CEO,
Royal Phillips

AMRIT NAGPAL
Managing Director,
Redmile Group

DAN RABINOVITSJ
Vice President
Connectivity, Meta

JOSEPH SIROSH, PHD
Vice President,
Alexa Shopping, Amazon

Meta amazon PHILIPS

MIT BAYER Shire

Microsoft illumina HARVARD UNIVERSITY

Absci is leading the way in AI drug creation towards breakthrough therapeutics at the click of a button



absci®



WANT TO LEARN MORE? LINKS TO:

- Absci Corporate Presentation
- Absci R&D Day 2023:
  - Presentation
  - Webcast Replay

This revolution is only just beginning.